Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
European Journal of Cancer.
Times cited: 2
Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the PI3K/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma.
Journal of Clinical Oncology.
Times cited: 32